Zhou et al. found that CDK4 gene was amplified in 65 MM patients and Palbociclib, an inhibitor of CDK4/6, effectively blunted the tumors harboring Cdk4 copy number gain in a PDX model [29]. This evidence concerns the gene CDK4 and Miyoshi myopathy.